Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model
- 5 December 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 640, 80-87
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Bureau of Chengdu (2019-YF08-00308-GX)
This publication has 27 references indexed in Scilit:
- The past and future of haemophilia: diagnosis, treatments, and its complicationsThe Lancet, 2016
- In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficienciesInternational Journal of Laboratory Hematology, 2016
- Hemophilia A treatment: disruptive technology aheadBlood, 2016
- The factor VIII protein and its function.Acta Biochimica Polonica, 2016
- Shear-Dependent Interactions of von Willebrand Factor with Factor VIII and Protease ADAMTS 13 Demonstrated at a Single Molecule Level by Atomic Force MicroscopyAnalytical Chemistry, 2015
- Do PT and APTT sensitivities to factors' deficiencies calculated by the H47‐A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?International Journal of Laboratory Hematology, 2015
- Turoctocog alfa (NovoEight®) – from design to clinical proof of conceptEuropean Journal of Haematology, 2014
- Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trialBlood, 2013
- Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotypeBlood, 2013
- Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complexBlood, 2002